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Summary
Haemorrhage, including intracranial bleeding, is a common, poten-
tially lethal complication of warfarin therapy and rapid and complete
reversal of anticoagulation may be life-saving. Fresh frozen plasma
(FFP) and vitamin K are most frequently administered. Because of the
variable content of vitamin K-dependent clotting factors in FFP, and
the effects of dilution, the efficacy of this approach is open to doubt.
We have therefore compared the effects of FFP and clotting factor con-
centrates on the INRs and clotting factor levels of orally anticoagulated
subjects requiring rapid correction of their haemostatic defect. In many,
the pre-treatment INR was considered to be dangerously above the tar-
get therapeutic ränge. In the 12 patients given FFP, the INR did not
completely correct (ränge 1.6-3.8, mean 2.3) indicating an ongoing
anticoagulated state in all. In contrast, the INR in 29 subjects given clot-
ting factor concentrates was completely corrected in 28 (ränge 0.9-3.8,
mean 1.3). Following treatment, marked differences were observed in
clotting factor IX levels between the two groups. The median factor IX
level was 19 u/dl (ränge 10-63) following FFP infusion and 68.5 u/dl
(ränge 31-111) following concentrate. In FFP treated patients, poorer
responses were also observed for each of the other vitamin K-depen-
dent clotting factors but these were less marked than for factor IX,
which was present in low concentrations in some batches of FFP. Thus,
haemostatically effective levels of factor IX cannot be achieved, in
most instances, by the conventional use of FFP in patients requiring re-
versal of their anticoagulant therapy. Clotting factor concentrates are
the only effective Option where complete and immediate correction of
the coagulation defect is indicated in orally anticoagulated patients with
life or limb-threatening haemorrhage.
Introduction
The therapeutic value of oral anticoagulants for the treatment of
acute venous thromboembolism is well established. More recently, the
demonstration of their value äs thromboprophylactic agents has result-
ed in an expansion in use, especially for stroke prevention, in subjects
with atrial fibrillation and in the secondary prevention of myocardial in-
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farction. World-wide, the number of individuals receiving warfarin is
increasing rapidly.
Optimal oral anticoagulant dosage regimens reflect a balance
between the antithrombotic effects of these drugs and their unwanted
haemorrhagic side effects. Haemorrhage is a common, important and
potentially lethal complication of oral anticoagulant therapy (1-3).
Logic dictates that rapid and complete reversal of the anticoagulant
effect could be life-saving in the case of intracranial haemorrhage.
There are surprisingly few studies of the clinical and haematological
efficacy of the various therapeutic options for the treatment of serious
bleeding episodes in overanticoagulated patients, or where rapid rever-
sal of oral anticoagulation is otherwise required, and there are no clear-
ly validated guidelines for the management of these patients.
In this study we have attempted to provide a rational basis for the
reversal of overanticoagulation with blood products by comparing the
effect of fresh frozen plasma (FFP) and clotting factor concentrates on
the clotting factor abnormalities of overanticoagulated patients who
had serious haemorrhage, or in those in whom there was an urgent
clinical requirement for reversal of the anticoagulated state.
Patients and Methods
Forty-one patients, 15 males and 26 females, aged 21-88 years were studied.
All were admitted into the Royal Hallamshire Hospital, Sheffield during the
period 1991-1994 for the management of haemorrhage directly attributable to,
or compiicated by, oral anticoagulants, or for urgent reversal of their warfarin
therapy. In all instances, immediate reversal of oral anticoagulant therapy was
considered necessary by the admitting clinical team. Clotting factor concen-
trates were administered to 29 patients considered to have life-threatening
haemorrhage or who required urgent anticoagulant reversal. These comprised
16 cerebral/spinal bleeds, 5 gastrointestinal bleeds with shock, 4 mtra-abdomi-
nal bleeds, and 4 others. Data were also available on 12 similar subjects who
received fresh frozen plasma (FFP).
FFP was supplied by the Trent Regional Blood Transfusion Service. Pa-
tients allocated to receive this product were each given 4 units (approximately
800 ml) intravenously.
Clotting factor concentrates were obtained from two manufacturers. Before
1993, patients received a prothrombin complex concentrate (9A, BPL, UK,
which contains factors II, IX, X) and also, a specific factor VII concentrate
(BPL, UK). Subsequently, Prothromplex T (Immuno, Vienna), which contains
clotting factors II, VII, IX and X, was used. Sixteen patients received Prothrom-
plex T and 13 received the BPL products. The dose administered, for both 9A
and Prothromplex T, was based on the factor IX content of the product and was
approximately 25-50 units factor IX/kg estimated body weight. This was
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Table l Changes in the vitamin K-dependent clotting factors and INR follow-
ing the administration of approximately 800 ml FFP in warfarin-treated pa-
tients. All clotting factor values in iu/dl
Patient
1
2
3
4
5
6
7
8
9
10
11
12
Mediän
Range
Factor II
pre post
3 12
I 14
4 21
17 33
2 14
3 12
11 16
30 29
8 19
3 17
1 19
3 17
1-30 12-33
Factor VII
pre post
5 12
18 42
0 26
33 47
7 15
3 9
24 27
65 59
2 9
5 25
5 19
5 19
0-65 9-59
Factor IX
pre post
4 12
17 32
0 21
47 63
6 10
12 19
22 36
62 62
9 13
10 20
6 13
- -
10 19
0-62 10-63
Factor X
pre post
0 20
2 20
0 23
13 27
9 17
6 18
10 24
10 22
18 29
2 15
1 18
6 20
0-18 15-29
INR
pre post
15.3 2.8
6.2 1.8
20 2.3
2.9 1.7
11.1 2.0
17.1 3.4
3.4 2.0
3.1 1.9
10.1 3.8
7.8 2.5
22 2.0
3.7 1.6
8.95 2.0
2.9-22 1.6-3.8
predicted to elevate plasma factor IX level by 25-50 iu/dl. Patients treated with
factor VII concentrate received 20-30 units/kg.
All patients received intravenous vitamin K, 1-5 mg. For the concentrate
recipients this was administered simultaneously with blood product replace-
ment. For those receiving FFP, vitamin K was given after administration of
the FFP and simultaneously with sampling for the second INR estimation, i.e.
15 min after completion of the FFP infusion.
In all instances the INR was determined immediately before treatment and
at approximately 15 min after completion of the replacement infusion.
In addition to the INR determinations, assays for the vitamin K-dependent
clotting factors II, VII, IX and X were performed in 14 patients who received
clotting factor concentrates and in 11 patients who received FFP. Standard one-
stage methods were employed. Prothrombin times for INR determination were
performed using a rabbit brain thromboplastin (Instrumentation Laboratory:
ISI approximately 1.2).
The relationship between INR and factor IX levels was studied in 25 pa-
tients who received either FFP (n = 11) or clotting factor concentrates (n = 14).
Only pre-treatment values were included. In order to examine the relationship
in greater detail, factor IX levels were also determined in an additional 19 plas-
ma samples from anticoagulated patients attending an anticoagulant clinic.
The association between INR determination and factor IX level was
assessed by linear regression, with factor IX level äs the dependent (y-axis) and
INR äs the independent (x-axis) variable. A possible difference between the
two groups of patients, i.e. those who did not receive FFP and those who did,
was studied by entering group (0, 1) äs a second independent variable. The
results of the regression analysis are expressed in the regression coefficients,
with 95% confidence intervals and significance tests bases on the Standard
errors of these coefficients.
Finally, the concentrations of factors II, VII, IX and X were determined in
20 different batches of FFP, supplied by the Trent Regional Blood Transfusion
Service.
Results
Coagulation Responses to FFP
The mean pre-treatment INR of the 12 patients who received FFP
was 10.2 (ränge 2.9-22.0). Fifteen min post FFP infusion the mean INR
was 2.3 (ränge 1.6-3.8).
The vitamin K-dependent clotting factors II, VII, 'IX and X were
determined before and after treatment in 11 FFP recipients. Mediän
pre-treatment values were 3.0,5.0,10.0 and 6.0 u/dl respectively. Cor-
responding values after treatment with FFP were 17.0, 19.0, 19.0 and
20.0 u/dl. Füll details are presented in Table l.
Coagulation Responses to Clotting Factor Concentrates
The mean pre-treatment INR of the 29 concentrate recipients was
5.8 (ränge 2.2-20). Fifteen min post-infusion the mean INR was 1.3
(ränge 0.9-3.8). Clotting factors II, VII, IX and X were also determined
before and after treatment in 14 concentrate recipients. Mediän
pre-treatment values were 15.0, 23.0, 35.5 and 14.5 u/dl respectively.
Corresponding values after treatment with clotting factor concentrates
were 50.0, 74.0, 68.5 and 72.0 u/dl. Füll details of the responses are
presented in Table 2.
There was no clinical or haematological evidence of disseminated
intravascular Coagulation in any of the treated patients.
Relationship between INR and Factor IX Levels
In patients treated with warfarin and who had not received replace-
ment therapy (Fig. 1) the INR clearly predicted the factor IX concentra-
tion (ß=-2.80, CI95% -3.6 to -l.9) i.e. factor IX = 45.33 -2.8 X INR.
In patients who had received FFP we observed an association in the
same direction (ß = -14.95) which, however, was not signiflcant
(p = 0.09). After investigating INR äs a predictor of factor IX in the
two groups of patients separately we set up a regression model with
both INR and patient group äs predictor variables. This analysis allows
us to assess, for a given INR, the association between patient treatment
group and factor ΓΧ levels. When the patient group was entered into the
analysis, this itself proved to be a significant predictor of the factor IX
concentration (p = 0.04). The relationsKip between INR and factor IX
levels for the two groups is therefore signifkantly different. The mean
FIX level in patients prior to anticoagulant reversal was 26.45 u/dl and
the mean INR was 6.73 compared to post-FFP treatment where the
mean FIX was 27.36 u/dl and the mean INR was 2,38' Thus for almost
identical factor IX levels in the pre and post-treatmeht patients the
equivalent INRs were very different.
Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Mediän
Range
Factor II
pre post
18 100
10 68
26 87
16 51
7 100
26 52
13 65
12 75
0 50
25 81
32 112
0 94
15 59
15 50
0-32 50-112
Factor VII
pre post
23 130
19 84
23 84
23 68
11 36.
32 105
19 41
26 72
27 76
2 37
39 113
33 92 \
0 50
1 19
23 74
0-39 19-130
Factor IX
pre post
62 90
37 111
23 65
55 92
20 31
36 89
54 67
41 75
35 70
5 31
23 62
40 87
6 46
28 46
35.5 68.5
5-62 31-111
Factor X
pre post
28 96
7 95
14 86
19 68
20 43
5 94
20 45
0 62
7 76
3 49
20 58
15 84
0 84
16 68
14.5 72
0-28 43-96
INR
pre post
2.3 1.1
3.3 1.0
4.0 1.2
2.4 1.2
2.9 1.4
4.3 1.0
2.2 1.3
3.4 1.1
4.0 1.0
14 1.4
2.9 1.3
2.5 1.1
14 M
9.7 11.4
3.35: 1.2
2.2-14.0 1.0-1.4
Table 2 Changes in the vitamin K-
dependent clotting factors and INR
following the administration of pro-
thrombin complex concentrate to
warfarin-treated patients. All clotting
factor values in iu/dl
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Clolting Factor Concentrations in FFP
The ränge and median concentrations of clotting factors Π, VII, IX
and X in 20 batches of FFP was 53-121 (82.5), 41-140 (92.0), 32-102
(61.0) and 61-150 (90.5) u/dl respectively. The median volume of the
batches was 200 ml (ränge 150-237 ml). The factor IX concentration of
5 of the 20 batches of FFP was below the lower limit of the normal
ränge for our laboratory (62 u/dl).
Discussion
There is a growing number of indications for oral anticoagulant
therapy and more individuals are receiving these drugs. Antithrombot-
ic benefits need to be considered against the risk of bleeding, since life-
threatening haemorrhage, and particularly intracranial haemorrhage, is
a frequent complication (4). This risk has recently been quantitated by
van der Meer and his colleagues (3), in 6800 patients. Haemorrhagic
complications ocpurred at a rate of 16.5 per 100 treatment-years. The
frequency of major bleeds was 2.7 per 100 treatment-years. Haemor-
rhagic complications increased significantly with age and showed a
relationship with increasing INR. More recently, in a case-control study
designed to explore the rational use of oral anticoagulants, particularly
in the elderly (4), the risk of intracranial haemorrhage was shown to rise
dramatically when the prothrombin time ratio, expressed äs an INR
equivalent, exceeds 4.0. Based on these data, Hylek and coworkers (4)
concluded that an INR greater than 4.0 carries an absolute risk of intra-
cranial haemorrhage of 2% per year. It is not always appreciated that
there is a markedly increased age-related sensitivity to oral anticoagu-
lants (5,6), and with increasing use of these agents in the elderly, one
can confidently predict an increasing number of hospital admissions
and a requirement for effective, rapid reversal of the coagulopathy.
Although serious and potentially life-threatening haemorrhage is a
well recognised complication of oral anticoagulant therapy there are
few studies which have compared the efficacy of methods of antico-
agulation reversal and there are no universally acceptable guidelines for
the emergency treatment of overanticoagulated patients. For this reason
we have compared the effects of fresh frozen plasma and clotting factor
concentrates on the INR and plasma levels of individual vitamin K-
dependent clotting factors of patients admitted into hospital for reversal
of their anticoagulant therapy. Although not a randomised study of clin-
ical outcome, the mode of treatment was determined by the preference
of the managing clinician in each case, thus allowing an analysis of the
effects of the two treatments on Wood coagulation.
The mean pre-treatment INR of the patients receiving FFP was
greater than that of the group receiving concentrates because the latter
group included patients whose anticoagulation control was initially
satisfactory but for whom urgent anticoagulant reversal was required on
account of head injury or unrelated emergency surgery. The infusion of
FFP resulted in a significant reduction of the mean pre-treatment value
of 10.2 to a mean post-treatment value of 2.3. In comparison, following
the administration of clotting factor concentrates the mean pre-treat-
ment INR of 5.8 was corrected to a mean value of l.3. If complete cor-
rection of the coagulopathy is considered to be advantageous, clearly
this is more likely to be achieved by the use of concentrates.
The INR system of monitoring oral anticoagulant control is based on
the prothrombin time test, introduced by Quick in 1935 (7). This test is
sensitive to reductions of the vitamin K-dependent clotting factors II,
VII and X but not to a reduction of factor IX. We have demonstrated an
inverse curvilinear relationship between INR (Fig. 1) and factor IX in
warfarin-treated subjects with levels of factor IX falling below 40 u/dl
100
90
80
70
60
50
40
30
20'
10
0
10 >10
INR
Fig. l Relationship between INR and factor IX levels m patients anticoagulat-
ed with warfann
70
60
50
40
30
20
10
l
10 15 20 25
INR
Fig. 2 Relationship between INR and factor IX levels m warfarin-treated
subjects following treatment with FFP. Circles represent values prior to FFP
administration and squares represent values following FFP
äs the INR exceeds 3.0. Also, our data show that in anticoagulated
patients, the INR predicts the plasma factor IX level. This relationship
is significantly altered and the relationship no longer holds when pa-
tients are treated with FFP (Fig. 2). The INR System of reporting oral
anticoagulant control is designed specifically for stably anticoagulated
patients, and is an mappropriate test following replacement therapy
with either plasma or clotting factor concentrates. Following the admin-
istration of plasma, the determination of an INR alone therefore pro-
vides an inadequate assessment of the haemostatic defect. This is clear-
ly illustrated by this study in that the reasonably satisfactory correction
of the INR, by plasma, was not accompamed by a similar correction of
factor IX, further supporting the use of concentrates in this Situation.
Although it is generally acknowledged that major differences exist
between the effective haemostatic concentrations of different clotting
factors, for most, precise information on this is scanty. Exceptions are
clotting factors VIII and IX, experience of which has been gained
through treatment of patients with haemophilia A and B respectively.
For both of these disorders, urgent restoration of the clotting factor
defect to normal values is considered mandatory in life-threatening
haemorrhagic situations (8). Clearly it is not logical to apply different
therapeutic principles to acquired factor IX deficiency. In respect of
factor IX, it is well established that a dose of l m/kg body weight is
required to elevate plasma factor IX levels by l iu/dl (8). 800 ml of FFP
with a factor IX concentration of 61 iu/dl would therefore yield 488 iu
factor IX. The calculated mcrease in factor IX in a 70 kg adult would
therefore be approximately 7 u/dl. This is dose to the median increment
of 9.0 u/dl which was observed in the eleven patients who received
FFP. The results described here in patients receivmg fresh frozen
plasma are therefore similar to those based on calculations which apply
to the recovery of factor IX in subjects with haemophilia B. If the same
therapeutic principles are applied to overanticoagulated patients äs to
those with haemophilia B it is clear that the reversal of factor IX levels
in overanticoagulated patients by fresh frozen plasma is not usually
possible where the INR is greater than 5.0. An increase in the volume of
FFP administered, in the emergency Situation, could be unsafe and
would not have an effect comparable to Infusion of concentrate. The
haemostatic response to FFP is influenced by plasma dilution and also
by the clotting factor concentration of the infused plasma. It is note-
worthy that the concentration of factor IX in each of the twenty differ-
ent batches of FFP was the lowest of any of the four vitamin K-depen-
dent clotting factors with a median factor IX concentration of only
61 u/dl. This compares with 82.5, 92.0, and 90.5 u/dl for the other
vitamin K-dependent clotting factors.
Our results in anticoagulated patients are similar to those obtained
by Mannucci and co-workers in 1979 (9), who compared the relative
effects of fresh frozen plasma and prothrombin complex concentrates in
correcting the haemostatic defect in patients with chronic liver disease.
These workers also reported that a dose of 12 ml/kg body weight FFP
was relatively ineffective in correcting the haemostatic defect and
although they did not assay the factor IX concentration of the FFP, the
recovery of this clotting factor, and also that of the other vitamin
K-dependent factors was similar to that described by ourselves.
It could be argued that the concentrate-related clotting factor
responses were influenced by vitamin K which was given simultane-
ously and approximately 20 min earlier than in the plasma-treated pa-
tients. Since effective correction of the coumarin effect by intravenous
vitamin K is achieved only after some hours and since the measured
clotting factor responses to concentrates were close to the predicted
values, we believe that the influence of vitamin K on our findings has
been negligible.
Although clotting factor concentrates are more effective than plasma
in reversing the haemostatic defect of oral anticoagulants their use is
not without potential liazard. Currently, prothrombin complex concen-
trates are being replaced by high purity factor IX products for the treat-
ment of subjects with haemophilia B. The main impetus for this change
is thromboembolism which is now recognised äs a complication of
these products (10). Although venous thromboembolism is an undoubt-
ed complication of prothrombin complex concentrates the magnitude of
this risk remains to be established since in individuals with haemo-
philia B, the occurrence of thrombosis has been confined to situations
where other mechanisms of coagulation activation are operating. These
include major surgery and trauma. Over many years PCCs have been
used extensively for the treatment of subjects with haemophilia B and
apart from the above mentioned situations we are unaware of any
reports of thrombosis complicating the routine use of these products.
We have demonstrated that the near correction of the INR in over-
anticoagulated patients by plasma is potentially misleading in that it
provides no Information in respect of factor IX, the concentration of
which is only minimally increased by this treatment. In clinical situa-
tions where reversal of the oral anticoagulant effect is an urgent prior-
ity, it is clearly not feasible to await results of individual clotting factor
assays. In view of the very low levels of this clotting factor in subjects
with an INR in excess of 5.0 it is clear that fresh frozen plasma is of
extremely limited efficacy in the correction of the coagulopathy in
overanticoagulated patients with serious bleeding necessitating reversal
of anticoagulation. It therefore follows that, in the absence of data from
a controlled trial with clinical outcome measures, in life-threatening
situations the use of clotting factor concentrates, not plasma, is indi-
cated. The advantage of complete and immediate reversal of the coagu-
lopathy is likely to result in clinical benefit in this emergency Situation.
We would therefore recommend that all hospitals treating subjects with
oral anticoagulants should retain Stocks of appropriate clotting factor
concentrates for emergency use. In view of the potential thrombotic
risk of this material, we would advocate caution in the dose of product
used. Although there has been a very great improvement in the viral
safety of clotting factor concentrates, pharmacovigilance should be
raaintained.
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